C.R. Bard, Inc. (BCR) Shares Sold by Advantus Capital Management Inc

Advantus Capital Management Inc cut its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,241 shares of the medical instruments supplier’s stock after selling 100 shares during the period. Advantus Capital Management Inc’s holdings in C.R. Bard were worth $1,800,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Fundsmith LLP boosted its stake in C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock valued at $633,996,000 after buying an additional 52,272 shares during the period. Putnam Investments LLC boosted its stake in C.R. Bard by 1.3% in the fourth quarter. Putnam Investments LLC now owns 1,171,703 shares of the medical instruments supplier’s stock valued at $263,235,000 after buying an additional 15,255 shares during the period. FMR LLC boosted its stake in C.R. Bard by 4.2% in the first quarter. FMR LLC now owns 986,276 shares of the medical instruments supplier’s stock valued at $245,129,000 after buying an additional 39,817 shares during the period. APG Asset Management N.V. boosted its stake in C.R. Bard by 22.7% in the first quarter. APG Asset Management N.V. now owns 844,466 shares of the medical instruments supplier’s stock valued at $209,884,000 after buying an additional 156,353 shares during the period. Finally, Norges Bank bought a new stake in C.R. Bard during the fourth quarter valued at approximately $141,560,000. Institutional investors and hedge funds own 87.63% of the company’s stock.

C.R. Bard, Inc. (NYSE BCR) traded down 0.12% during mid-day trading on Monday, reaching $319.65. The company’s stock had a trading volume of 170,760 shares. The company has a market capitalization of $23.15 billion, a PE ratio of 40.68 and a beta of 0.59. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $320.37. The firm has a 50 day moving average price of $311.80 and a 200-day moving average price of $264.06.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The company had revenue of $938.80 million for the quarter, compared to the consensus estimate of $916.15 million. During the same quarter in the previous year, the business earned $2.34 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities analysts predict that C.R. Bard, Inc. will post $11.78 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Stockholders of record on Monday, July 24th will be paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.21%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/07/18/c-r-bard-inc-bcr-position-lowered-by-advantus-capital-management-inc-updated.html.

Several equities research analysts have recently commented on BCR shares. Jefferies Group LLC restated a “hold” rating and set a $237.00 price target on shares of C.R. Bard in a research note on Monday, March 27th. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a research note on Monday, June 12th. BMO Capital Markets restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. Morgan Stanley cut C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Finally, Raymond James Financial, Inc. reiterated a “market perform” rating and issued a $265.00 price objective on shares of C.R. Bard in a research report on Tuesday, April 25th. Eleven analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company’s stock. C.R. Bard has an average rating of “Hold” and an average price target of $271.31.

In other news, VP Frank Lupisella, Jr. sold 3,622 shares of the business’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total value of $1,101,088.00. Following the sale, the vice president now owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.80% of the stock is currently owned by insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply